Led · Equity · Sep 2023

Founded in 2018 by Jesse Joonho Lim and Ken Daehyun Pak, Petnow offers an Android and iOS app that creates biometric profiles of pets by scanning faces and snouts. The company says its AI is trained on roughly 200,000 images collected by the team and users, and it automatically detects and crops pet images for analysis. For dogs Petnow records a "nose print," which it compares to human fingerprints, and it points to a 2021 IEEE Access study showing its dog nose‑print method was over 99% accurate; a companion paper for cats is forthcoming. Petnow claims its algorithms are 99% accurate overall and says it optimizes photo quality at capture; it also provides options for user consent and data deletion. The startup has about 70,000 users, has signed five undisclosed enterprise and public-sector customers in France, Toronto and South Korea, and is pre-revenue with a roughly $150,000-per-month burn rate. Planned commercial moves include anticipated contracts with Korean domestic and international pet insurers by October and pilots for pet registries in France and a Canadian metropolitan government.

Participated · Series B · Oct 2020

Ilias Biologics develops exosome-based therapeutics using its EXPLOR® platform, a novel protein-loading method that enables free-form loading of large therapeutic proteins into exosome lumens. The company’s lead candidate, ILB-202, produced promising preclinical data published in Science Advances, and Ilias secured a key exosome engineering patent from the USPTO in July. The Series B proceeds will support continued development of the EXPLOR platform and advancement of its exosome therapeutics pipeline across inflammatory diseases and oncology. Ilias plans to submit an IND to the U.S. FDA and initiate a first-in-human clinical trial by the second half of 2021 targeting an undisclosed acute inflammatory disease, and is in active discussions with multiple pharmaceutical companies for potential collaborations. Financially, the company has raised a total of $40.2M since its foundation in November 2015. Management is led by CEO Dr. Chulhee Choi and is planning an IPO on KOSDAQ in Q1 2022, with underwriter contracts being finalized.

Participated · Series A · Dec 2018

Point2 Technology develops RF signaling-based interconnect platforms—branded Active RF Cable and e-Tube—that use RF over plastic waveguides to connect accelerators and scale rack-level compute. Its technology aims to extend reach compared with copper, lower power and cost versus optical approaches, and deliver ultra-low latency without laser-based systems. The platform supports multiple form factors including pluggable cables, near-package modules, and co-packaged solutions for accelerator-to-accelerator communication. Point2 is moving from development toward commercialization and deployment and is expanding engineering and systems teams to support that transition. The company has garnered industry recognition such as a BloombergNEF Pioneers award and recently raised $76 million in a Series B extension to fund commercialization and continued product development.